Kolumne, ORE

Original-Research: 029 Group SE - from NuWays AG Classification of NuWays AG to 029 Group SE Company Name: 029 Group SE ISIN: DE000A2LQ2D0 Reason for the research: Update Recommendation: Halten from: 22.05.2024 Target price: EUR 14.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Christian Sandherr FY23 as expected / / key holding with favourable developments Topic: 029 published FY23 figures.

22.05.2024 - 09:02:36

Original-Research: 029 Group SE (von NuWays AG): Halten


Original-Research: 029 Group SE - from NuWays AG

Classification of NuWays AG to 029 Group SE

Company Name: 029 Group SE
ISIN: DE000A2LQ2D0

Reason for the research: Update
Recommendation: Halten
from: 22.05.2024
Target price: EUR 14.00
Target price on sight of: 12 Monaten
Last rating change: 
Analyst: Christian Sandherr

FY23 as expected // key holding with favourable developments
 
Topic: 029 published FY23 figures. As 029 holds only minority stakes and
reports under German HGB (no mark-to-market valuation), it was a non-event.
Yet, its key assets continue to perform well. As 029 had no divestments
during FY23 (Emerald Stay was sold in Feb. 2024), the company generated no
sales. Operating expenses amounted to roughly EUR 0.6m, slightly less than
last year due to the absence of listing related costs. Going forward, we
expect the annual cost base to come in at similar levels.
 
Yet, this does not include one-off expenses related to potential
investments/divestments. While cash at hand stood at only EUR  10k at the end
of the year, the EUR 1.6m inflow from the Emerald divestment should provide
029 with sufficient liquidity.
 
The group's key assets, Limestone Capital and TRIP Drinks (eNuW: 95% of the
implied fair NAV) remain on a strong growth path. TRIP (10% of NAV, eNuW),
the CBD-infused drink is available at more than 25k stores across the UK,
France and the US. As a result, sales have grown at 390% p.a. during the
past two years to roughly GBP 20m. Despite the changed interest rate
environment, we would expect any potentially upcoming funding rounds to
value the company at more than EUR 140m (industry's transaction median stands
at ~ 10x sales). TRIP is well on the way to continuing its growth
trajectory. If TRIP keeps growth at a similar level, the valuation has a
lot of room for upside. They just launched a new nonCBD-based product
("Mindful Blend") and focus on further expansion (e.g., in the US).
 
Limestone Capital (85% of NAV, eNuW) seems well on track to expand its
hotel portfolio. In fact, the company has just purchased a hotel in Madrid.
Thanks to its ongoing funding round, Limestone should be able to grow to 20
hotels, operated by its own brand aethos, until the end of 2025e, in our
view.
 
First divestment completed. As a reminder, in February, 029 sold it's 5.2%
stake in Emerald Stay. The transaction is expected to generate roughly EUR
1.6m gross proceeds, reflecting a realized multiple on the FY23 book value
of around 2.3x and 2.7x on the invested capital. This was carried by the
recently strongly increasing number of vacation rentals on the platform
(FY23e: +71% yoy), in our view. The EUR 0.9m book gain should positively
impact 029's FY24 H1 figures due at the end of September.
 
We confirm our HOLD rating with an unchanged EUR 14 PT based on based on a
sum-of-the-parts valuation (see page 2) with a 5% holding discount.

You can download the research here:
http://www.more-ir.de/d/29845.pdf
For additional information visit our website
www.nuways-ag.com/research.

Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------transmitted by EQS Group AG.-------------------


The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.

@ dpa.de

Weitere Meldungen

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)... Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to MPH Health Care AG Company Name: MPH Health Care AG ISIN: DE000A289V03 Reason for the research: Q1 & 2023 Ergebnisse Recommendation: Kaufen from: 12.06.2024 Target price: EUR113 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. (Boerse, 12.06.2024 - 14:46) weiterlesen...

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy Original-Research: Vidac Pharma Holding Plc - from Sphene Capital GmbH Classification of Sphene Capital GmbH to Vidac Pharma Holding Plc Company Name: Vidac Pharma Holding Plc ISIN: GB00BM9XQ619 Reason for the research: Initiation of Coverage Recommendation: Buy from: 12.06.2024 Target price: EUR 4.90 Target price on sight of: 36 months Last rating change: - Analyst: Peter Thilo Hasler Reversal of the abnormal metabolism of cancer cells We initiate research coverage of the shares of Vidac Pharma Holding plc with a Buy rating and a price target of EUR 4.90 (base case scenario). (Boerse, 12.06.2024 - 14:36) weiterlesen...

Original-Research: Koenig & Bauer AG (von Montega AG): Kaufen Original-Research: Koenig & Bauer AG - von Montega AG Einstufung von Montega AG zu Koenig & Bauer AG Unternehmen: Koenig & Bauer AG ISIN: DE0007193500 Anlass der Studie: Update Empfehlung: Kaufen seit: 12.06.2024 Kursziel: 17,00 EUR (zuvor: 16,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Patrick Speck (CESGA) Super drupa - Weltleitmesse bringt erhofften Auftragsschub Koenig & Bauer hat am Montag nach Börsenschluss über einen starken Auftragseingang infolge der jüngst zu Ende gegangenen Weltleitmesse drupa berichtet. (Boerse, 12.06.2024 - 10:31) weiterlesen...

Original-Research: ÖKOWORLD AG (von BankM AG): Kaufen Original-Research: ÖKOWORLD AG - von BankM AG Einstufung von BankM AG zu ÖKOWORLD AG Unternehmen: ÖKOWORLD AG ISIN: DE0005408686 Anlass der Studie: GB 2023, Basisstudien-Update Empfehlung: Kaufen seit: 11.06.2024 Kursziel: EUR 52,52 Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: Keine Analyst: Daniel Großjohann und Dr. (Boerse, 11.06.2024 - 14:56) weiterlesen...

Original-Research: MS Industrie AG (von GBC AG): Kaufen Original-Research: MS Industrie AG - von GBC AG Einstufung von GBC AG zu MS Industrie AG Unternehmen: MS Industrie AG ISIN: DE0005855183 Anlass der Studie: Researchstudie (Anno) Empfehlung: Kaufen Kursziel: 2,75 EUR Kursziel auf Sicht von: 31.12.2024 Letzte Ratingänderung: Analyst: Cosmin Filker, Matthias Greiffenberger - Ultraschall-Segment soll mehrheitlich veräußert werden - Erhebliche Verbesserung des Net Debt erwartet - Umsatz- und Ergebnisprognosen der MS XTEC an aktuelle Marktlage angepasst Mit Ad-hoc-Mitteilung vom 31.05.2024 hat die MS Industrie AG bekannt gegeben, dass sich die Schunk Sonosystems GmbH mit Sitz in Wettenberg mit einer einfachen Mehrheit an der MS Ultraschall Technologie GmbH beteiligen wird. (Boerse, 11.06.2024 - 11:01) weiterlesen...

Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH... Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to CEL-SCI Corporation Company Name: CEL-SCI Corporation ISIN: US1508376076 Reason for the research: Update Recommendation: Buy from: 11.06.2024 Target price: USD 6.20 Target price on sight of: 12 months Last rating change: Analyst: Christian Orquera First Berlin Equity Research has published a research update on CEL-SCI Corporation (ISIN: US1508376076). (Boerse, 11.06.2024 - 10:36) weiterlesen...